FDA approved revumenib for KMT2A-rearranged relapsed or refractory acute leukemiaNov 10Regulatory decisionrevumenibSyndax Pharmaceuticals Inc
Syndax reports Q3 2026 results, 90% Revuforj revenue growth, CFO transitionNov 2Quarterly updaterevumenibSyndax Pharmaceuticals Inc
Syndax reports 2Q26 revenue growth, details EGFR and menin inhibitor pipeline additionsAug 4Quarterly updaterevumenibSyndax Pharmaceuticals Inc